Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPA and SafetyCall

This article was originally published in The Tan Sheet

Executive Summary

The Natural Products Association partners with SafetyCall adverse event reporting call center to offer association members reduced rates on reporting services in preparation for changes in reporting requirements due to the implementation of the dietary supplement AER law Congress passed in 2006, NPA announces Nov. 7 (1"The Tan Sheet" Dec. 18, 2006, p. 6). SafetyCall and NPA also plan to conduct education events to help companies comply with the regulation and "ease the transition," NPA says. "We're happy to partner with the Natural Products Association and work with their members at a time when there's a rush to conform to the new reporting requirements," SafetyCall President, Regulatory and Scientific Affairs, Richard Kingston says. "We're confident that we can meet the increased demand and quickly respond to and document adverse event reports on behalf of participating association member companies," Kingston says...

You may also be interested in...



Adverse Event System Success Will Depend On Trained Reporters, Experts Say

Training potential reporters of adverse events may be crucial to the effectiveness of a mandatory adverse event reporting system, industry stakeholders say

COVID-19 Vaccine Skycovion Among Raft Of New EU Filings

EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.

WHO Steps Up Drive To Build Local Drug & Vaccine Production In Lower-Income Countries

The COVID-19 pandemic has underlined the need for less well-resourced countries to improve access to medicines, vaccines, medical devices and other health products by building their own production capacities.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel